Jake Scott
@CancerConnector
Followers
5K
Following
6K
Media
2K
Statuses
30K
@CWRUSOM @OxUniMaths @ClevelandClinic Sarcoma #radonc #mathonco #mathevo @NavalAcademy submarine #veteran tweets=mine he/him TEDMED https://t.co/yBCRcx52pW
Cleveland, OH
Joined April 2012
🚨 New in @JClinInvest 🚨 HPV+ oropharynx patients do not all benefit equally from the same radiation dose. Our study shows that genomics (via GARD) can guide personalized RT de-escalation—safely sparing toxicity without losing cure. Paper 👉 https://t.co/TEOh9q6qYQ
#ASTRO25
3
19
38
Subcutaneous Amivantamab is FINALLY @US_FDA approved! This is huge for patients and families because it reduces both time and physical burden: 👉 Decrease infusion reaction & less VTE 👉 Potentially (exploratory and needs longer follow-up/confirmation) a greater efficacy vs IV
Subcutaneous Amivantamab now @US_FDA approved based off #PALOMA3 study: SubQ vs. IV Ami (with Lazertinib) in EGFR+ mNSCLC. - SubQ was non inferior to IV Ami-Laz - Fewer IRRs with SubQ - PFS 6.1mos (IV) & 4.3mos (SubQ). BUT OS better with SubQ (HR: 0.62) 🤔 #OncTwitter #lcsm
1
7
20
New in the December 15 issue from the Cancer Research special series: Spatially Discontinuous Mutation Topographies in #DCIS Reveal Noncompetitive Growth Dynamics, by Marc D. Ryser, Darryl Shibata, E. Shelley Hwang, and colleagues https://t.co/vzwgXEUNxc
0
2
2
A huge pleasure and honor to present in beautiful Israel. Thank you for your hospitality! #hope #HCC #SBRT
Truly an honor to have Dr Laura Dawson (past @ASTRO_org President!) speak at the Second Annual Radiation Oncology conference in @Israel today Her pioneering work on #radonc for liver cancers is truly remarkable @ldawsonmd
@eli_sapir
2
6
28
A sincere appreciation and acknowledgment to the 440 patients, investigators, and institutions who participated on this Phase III randomized trial highlighting the ability of proton therapy (IMPT) to de-intensify treatment and improve survival @MDAndersonNews
Results from a study led by @SJFrankMD found a survival benefit for patients with oropharyngeal cancers treated with proton therapy than the patients receiving traditional radiation therapy. More on the findings, published today in @TheLancet: https://t.co/rytepbPN8V
#EndCancer
2
14
54
President and CEO of @LUNGevity taking advocacy to the next level with 60,000 white flags planted on the National Mall this week, one for every 2 Americans dying from this disease every year. THIS COUNTRY CANNOT IGNORE LUNG CANCER ANYMORE!! 🇺🇸
3
8
45
This is nothing short of incredible, the power of science! 🧪 🧫🧬🔬🥼🥼
~88 million people have been infected with HIV in history This is the 7th person to be cured!
1
1
17
A multidisciplinary group of scientists at Northwestern University demonstrate how early detection LDCT scans could reach nearly 94% of people at risk for lung cancer if we ignored recommendations by the USPSTF. https://t.co/srjvrnHszs
2
8
21
Magnitude of benefit of SABR for EGFR+ disease is very similar to other treatments that are much more toxic @Mat_Guc
2
16
68
Some great news! @DrOlsonOncology ‘s SABR-COMET-3 completed accrual today!! 330 randomized with 1-3 Mets, primary endpoint OS. Biomarker studies led by @DrAlisonAllan and @DrCorreaRO. Readout maybe in 2027, with COMET10 likely in 2026.
8
25
143
Why are we not talking about this more? @safaviaa
Among patients with oropharyngeal squamous cell #carcinoma, proton therapy for head and neck cancer was associated with a higher 3-year incidence of osteoradionecrosis compared with intensity-modulated radiation therapy. https://t.co/HqxJ1yRlwp
4
7
20
I am very excited to announce that a fully funded PhD position is available in my group. Topic: Synergistic coevolution in mono-specific and multi-species microbial consortia Please RT or forward to interested candidates. Deadline: 11.01.26 More info: https://t.co/ve6SKoi2K7
5
101
251
High-Dose Versus Standard-Dose Twice-Daily Thoracic Radiotherapy in SCLC: Final data: Median OS in the 60 Gy group was significantly longer (43.5 versus 22.5 mo) Same toxicity. https://t.co/1PO08uUSKc
jto.org
Chemoradiotherapy is standard treatment for limited-stage SCLC. However, most patients relapse and there is a need for better treatment. We investigated whether twice-daily thoracic radiotherapy...
1
39
74
UCLA Radiation Oncology's Dr. @DrewMoghanaki emphasizes the national importance of lung cancer screening to the @nytimes in reference to a recent JAMA publication from scientists at the American Cancer Society. Read the piece here: https://t.co/pUD3OHib3t
0
8
14
@Mat_Guc showing data on the % of patients in oligomets RCTs where radiation was used as the treatment modality. Conclusion: the randomized data most strongly support the use of radiation rather than surgery or RFA
3
16
62
Congratulations to super ⭐️ @CleClinicMD #radonc PGY-3 resident @ElizabethEObi for receiving the Women in Neuro-Oncology (WiN) scholarship award at @NeuroOnc #SNO2025!
1
9
27
@AniBommireddy @CleClinicMD @ElizabethEObi @NeuroOnc Congratulations @ElizabethEObi on the accolade! @ARRO_org #CleClinicCancer
0
2
3
I’m glad to see JAMA is giving light to data and editorials that highlight how UNACCEPTABLE the rates of screening continues to be, while mountains of dead people keep piling up as intellectuals keep debating the “barriers” of lung screening. Please stand up and DO SOMETHING
.@alexandra_p_24, @LeciaSequist and I wrote a new editorial in JAMA ( https://t.co/bV1KF4bHmc) responding to a powerful #lungcancer screening study by Bandi et al ( https://t.co/AGqM52seY2). In 2024, only 18.7% of adults eligible for #lungcancerscreening in the U.S. were screened.
2
4
25
Outstanding talk by Dr. Erik Davies, PGY5 @CleClinicMD #radonc resident, on management of GI tumors during the 27th Annual Best of Radiation Oncology Update! Super proud that you will focus on GI tumors @DukeRadOnc next year! @ARRO_org #CleClinicCancer
0
6
27
@DrewMoghanaki shows us why more patients with early stage #lungcancer will have SABR over surgery -#SABR2025
1
25
68
Interesting slide! #SABR2025
@DrewMoghanaki shows us why more patients with early stage #lungcancer will have SABR over surgery -#SABR2025
1
13
42